Brief: Innovation Pharmaceuticals Announces Overseas Regulatory Filing Submitted For Covid-19 Clinical Study
16/11/2020 14:03
Nov 16 (Reuters) - Innovation Pharmaceuticals Inc IPIX.PK :
* INNOVATION PHARMACEUTICALS ANNOUNCES OVERSEAS REGULATORY
FILING
SUBMITTED FOR COVID-19 CLINICAL STUDY
* INNOVATION PHARMACEUTICALS - PHASE 2 CLINICAL TRIAL OF
BRILACIDIN FOR COVID-19, ON TRACK TO COMMENCE IN 2020 UPON
GAINING REQUIRED APPROVALS
Source text for Eikon: ID:nGNX73418G
Further company coverage: IPIX.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovation Pharmaceuticals
See all newsBrief: Innovation Pharmaceuticals Announces New Milestone At Beamed On Track To File 510(K) Submission To FDA In Q2 2024
Brief: Innovation Pharmaceuticals Provides Update On US Patent Applications Covering Use Of Brilacidin In Inflammatory Bowel Diseases, Coronaviruses And Fungal Diseases
Brief: Innovation Pharma Reports Enrollment In Phase 2 Trial Of Brilacidin For COVID-19 Tops 70%
Brief: Innovation Pharma Surpasses 50% Enrollment In Phase 2 Clinical Trial Of Brilacidin For COVID-19
Brief: Innovation Pharma Completes Interim Safety Data Review